Search
Kiniksa Pharmaceuticals International PLC
KNSAAdd to Watchlist
79.150USD
+15.615+24.58%
Close 07-28 16:00（ET）Quotes delayed by 15 min
6.04BMarket Cap
81.35P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-28The current earnings forecast score of Kiniksa Pharmaceuticals International PLC is 8.75, ranking 9 out of 155 in the Pharmaceuticals industry. The average price target is 55.00, with a high of 62.00 and a low of 45.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
69.714
Target Price
+10.94%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Kiniksa Pharmaceuticals International PLC
KNSA
8
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Kiniksa Pharmaceuticals International PLC's expected revenue for the next quarter?
Kiniksa Pharmaceuticals International PLC's expected revenue is 240.84M.
What is Kiniksa Pharmaceuticals International PLC's price target?
Analysts forecast that Kiniksa Pharmaceuticals International PLC's price target is USD 55.00, with the highest forecast at USD 62.00 and the lowest forecast at USD 45.00.
How have Kiniksa Pharmaceuticals International PLCKNSA's recent earnings per share performed?
The market expectation was USD 0.33, while Kiniksa Pharmaceuticals International PLCKNSA's earnings per share (EPS) for the previous quarter was USD 0.30. EPS for the next quarter is expected at USD 0.35.
What is the analyst rating for Kiniksa Pharmaceuticals International PLC?
Based on the ratings of Kiniksa Pharmaceuticals International PLC's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.